×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
ContraFect halts phase 3 after antimicrobial fails futility test against MRSA
Fierce Biotech
ContraFect has revealed its phase 3 clinical trial has failed an interim futility analysis. The inability of the direct lytic agent to beat placebo triggered...
36 months ago
ContraFect submits IND for novel intravenous antibiotic
CIDRAP
Novel mechanism of action. In July 2020, ContraFect was awarded a grant by the Combating Antibiotic-Resistant Bacteria Biopharmaceutical...
21 months ago
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
Yahoo Finance
This milestone is significant for ContraFect and historic in the field of non-traditional antibacterial therapies, as CF-370 will be the first...
20 months ago
ContraFect begins Phase Ib/II clinical trial of exebacase
Clinical Trials Arena
The study will assess the safety, pharmacokinetics and efficacy of intra-articularly administered exebacase in patients with chronic PJI of the knee.
27 months ago
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million
GlobeNewswire
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million ... In consideration for the immediate exercise of the existing...
24 months ago
ContraFect Given Up to $18.9M to Advance CF-370 to Treat P. aeruginosa
Cystic Fibrosis News Today
CF-370 is the company's second lysin candidate, being developed for another of these ESKAPE pathogens, P. aeruginosa. The compound was selected...
59 months ago
ContraFect’s Staph infection drug may succeed in trial but caveats remain
Pharmaceutical Technology
Although ContraFect's Phase II CF-301 (exebacase) clinical trial for Staph aureus bloodstream infections including endocarditis may achieve the...
82 months ago
Pfizer Bought a Penny Biotech Stock Just Before It Doubled
Barron's
The pharma giant invested $3 million in ContraFect stock in mid-December, paying 27 cents a share. Pfizer is now the company's top holder.
66 months ago
ContraFect Corp Earnings Miss, Revenue In line In Q3
Investing.com
Investing.com - ContraFect (NASDAQ:CFRX) Corp reported on Monday third quarter earnings that missed analysts' forecasts and revenue that was...
32 months ago
ContraFect tries to find path forward for MRSA drug despite 'uninterpretable' phase 3 results
Fierce Biotech
Six months ago, ContraFect revealed that exebacase had failed an interim futility analysis in a phase 3 clinical trial called DISRUPT. In a new...
30 months ago